Abstract
Background
For women at increased risk of breast cancer, the National Comprehensive Cancer Network (NCCN) guidelines recommend clinical encounters every 6–12 months. While screening mammography has corresponded with a relative risk reduction in breast cancer mortality of approximately 20%, evidence validating clinical breast examination (CBE) as an efficacious screening modality is deficient. Our study aimed to assess the conventional merit of regular CBE for breast cancer detection among individuals at increased risk of breast cancer development.
Methods
Women > 18 years with documented high-risk encounters at Corewell Health West from 1 January 2018 to 31 December 22 were retrospectively reviewed. High-risk criteria included genetic predisposition, 5-year (> 1.7%) or lifetime (> 20%) Tyrer–Cuzick and/or Gail Model risk estimations, thoracic radiotherapy before age 30 years, lobular carcinoma in-situ, or atypical hyperplasia. Patients with a history of breast cancer or bilateral prophylactic mastectomy prior to 2018 were excluded.
Results
Of the 9171 cumulative high-risk encounters among 2493 women, only one breast cancer was detected by CBE. CBE resulted in 1 (0.04%) cancer diagnosis compared with 30 (1.2%) detected on screening imaging and 10 (0.4%) self-reported. Of the 30 image-detected cancers, 28 (93.3%) had no detectable clinical findings at the time of preoperative consultation. Self-reported and CBE-detected cancers were more likely to be of higher clinical stage compared with imaging-detected malignancies.
Conclusions
The role of routine CBE as a cancer detection modality in the high-risk patient population appears to be limited. Telemedicine can be offered to individuals who have completed screening imaging but are unable to commit and/or are inconvenienced by in-person high-risk breast cancer assessments.
References
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Screening and Diagnosis V.32023. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1421. Accessed March 1, 2024.
American Cancer Society. Cancer facts & figures 2024. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf. Accessed March 1, 2024.
Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–36. https://doi.org/10.3322/caac.21731.
Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;2013(6):CD001877. https://doi.org/10.1002/14651858.CD001877.pub5.
Tabár L, Dean PB, Chen TH, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2019;125(4):515–23. https://doi.org/10.1002/cncr.31840.
Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40. https://doi.org/10.1038/bjc.2013.177.
Autier P, Héry C, Haukka J, Boniol M, Byrnes G. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol. 2009;27(35):5919–23. https://doi.org/10.1200/JCO.2009.22.7041.
Qaseem A, Lin JS, Mustafa RA, et al. Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians [published correction appears in Ann Intern Med. 2023 Apr;176(4):584]. Ann Intern Med. 2019;170(8):547–60. https://doi.org/10.7326/M18-2147.
Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society [published correction appears in JAMA. 2016 Apr 5;315(13):1406]. JAMA. 2015;314(15):1599–614. https://doi.org/10.1001/jama.2015.12783.
Klarenbach S, Sims-Jones N, Lewin G, et al. Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer. CMAJ. 2018;190(49):E1441–51. https://doi.org/10.1503/cmaj.180463.
Anderson BO, Bevers TB, Carlson RW. Clinical breast examination and breast cancer screening guideline. JAMA. 2016;315(13):1403–4. https://doi.org/10.1001/jama.2016.0686.
Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review [published correction appears in JAMA. 2016 Apr 5;315(13):1406]. JAMA. 2015;314(15):1615–34. https://doi.org/10.1001/jama.2015.13183.
American Cancer Society Inc. Recommendations for the early detection of breast cancer. Published 19 December 2023. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html. Accessed 1 March 2024.
Menes TS, Coster D, Coster D, Shenhar-Tsarfaty S. Contribution of clinical breast exam to cancer detection in women participating in a modern screening program. BMC Womens Health. 2021;21(1):368. https://doi.org/10.1186/s12905-021-01507-x.
Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA. 1999;282(13):1270–80. https://doi.org/10.1001/jama.282.13.1270.
Oestreicher N, White E, Lehman CD, Mandelson MT, Porter PL, Taplin SH. Predictors of sensitivity of clinical breast examination (CBE). Breast Cancer Res Treat. 2002;76(1):73–81. https://doi.org/10.1023/a:1020280623807.
Mann RM, Hooley R, Barr RG, Moy L. Novel approaches to screening for breast cancer. Radiology. 2020;297(2):266–85. https://doi.org/10.1148/radiol.2020200172.
Shaver J. The state of telehealth before and after the COVID-19 pandemic. Prim Care. 2022;49(4):517–30. https://doi.org/10.1016/j.pop.2022.04.002.
Shaffer KM, Turner KL, Siwik C, et al. Digital health and telehealth in cancer care: a sco** review of reviews. Lancet Digit Health. 2023;5(5):e316–27. https://doi.org/10.1016/S2589-7500(23)00049-3.
Acknowledgement
The authors thank the Scholarly Activity Support Department for assistance with statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Hua, T., Mendoza, S., McCririe-Balcom, M. et al. Routine Clinical Breast Examination Is a Low-Yield Practice Among Women at High Risk of Breast Cancer. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15702-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1245/s10434-024-15702-1